AIM ImmunoTech Inc banner
A

AIM ImmunoTech Inc
AMEX:AIM

Watchlist Manager
AIM ImmunoTech Inc
AMEX:AIM
Watchlist
Price: 0.5172 USD -0.54% Market Closed
Market Cap: $4.2m

AIM ImmunoTech Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

AIM ImmunoTech Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
AIM ImmunoTech Inc
AMEX:AIM
Revenue
$88k
CAGR 3-Years
-15%
CAGR 5-Years
-12%
CAGR 10-Years
-4%
Abbvie Inc
NYSE:ABBV
Revenue
$61.2B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.4B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36.8B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$12B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
13%
No Stocks Found

AIM ImmunoTech Inc
Glance View

Market Cap
4.2m USD
Industry
Biotechnology

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The firm's products are Alferon N Injection and Ampligen. Alferon N Injection is a natural-source, glycosylated, multi-species alpha interferon product. Alferon is used for the treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Ampligen (rintatolimod), which is a drug of macromolecular RNA (ribonucleic acid) molecules, it is a sterile solution indicated for the treatment of severely debilitated patients with Chronic Fatigue Syndrome (CFS) who have been diagnosed for longer than one year. Ampligen is used in combination with checkpoint blockade therapies. Ampligen is also being used as a monotherapy to treat pancreatic cancer patients.

AIM Intrinsic Value
0.1776 USD
Overvaluation 66%
Intrinsic Value
Price $0.5172
A

See Also

What is AIM ImmunoTech Inc's Revenue?
Revenue
88k USD

Based on the financial report for Dec 31, 2025, AIM ImmunoTech Inc's Revenue amounts to 88k USD.

What is AIM ImmunoTech Inc's Revenue growth rate?
Revenue CAGR 10Y
-4%

Over the last year, the Revenue growth was -48%. The average annual Revenue growth rates for AIM ImmunoTech Inc have been -15% over the past three years , -12% over the past five years , and -4% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett